AQUA

ANALYST NOTE: AQUA (Evoqua Water Technologies Corp.) Date: 2026-06-13 Current Price: $49.88

1. Structural Readiness

State: Context-Only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 2.0% (Sub-threshold)

Analysis: As of the close on 2026-06-13, the structural setup for AQUA is not defined. The provided data indicates a "context-only" state with no active, forming, or invalidated coil structure recorded. Specifically:

• There is no confirmed breakout (Confirmed-Active).

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Macro Thesis: None

At this date, AQUA is classified as a Tactical, setup-led name. There is no named secular thesis attached to the position in the current evidence base. The investment case must be judged strictly on the quality of the technical setup (which is currently absent) and the underlying business fundamentals. No macro themes (e.g., "Water Scarcity," "Infrastructure Bill," "ESG Rotation") are currently active or assigned to this specific setup. The conviction stack relies entirely on the structural readiness of the price action and the strength of the business metrics, neither of which currently presents a complete picture for a high-conviction entry.

3. Business Analysis

Company Profile: Evoqua Water Technologies Corp. (AQUA) Industry: Industrial Water Treatment / Environmental Services Business Model: Integrated Solutions and Services (Capital Systems + Recurring Service/Aftermarket)

Operational Overview: AQUA delivers comprehensive solutions for water and wastewater management. The business operates across a diverse client base including manufacturing, healthcare, pharmaceuticals, biotechnology, power generation, microelectronics, chemical processing, food and beverage, and refining industries. The company operates both domestically in the United States and internationally.

Key Business Segments & Evidence:

• Integrated Solutions and Services: This division provides large-scale water treatment capital systems alongside ongoing support. This includes spare parts, consumables, and service agreements ranging from long-term contracts to urgent response services. The segment also handles odor and corrosion mitigation and provides drinking water purification systems for municipal use.
• Applied Product Technologies: This division supplies sophisticated filtration and separation technologies. Key products include VAF self-cleaning filters, Ionpure electrodeionization systems, and Vortisand filtration systems. The segment serves microelectronics, pharmaceutical, and power generation sectors with filter presses, consumables, and aftermarket components. It also provides disinfection solutions (chemical and non-chemical) and specialized aquatics/electrochlorination solutions.
• Revenue Mix: Service and aftermarket operations constitute approximately 60% of revenue, providing a stable, recurring revenue base.

Management Expectations (Source: Q4 2022 / FY 2023 Guidance):

• Backlog Growth: As of the last available earnings transcript (2023-01-31), the first-quarter backlog was up approximately $162 million (21% YoY) and up 3% versus Q4 of the prior year.
• Order Activity: Management expects the book-to-bill ratio to remain above one for the fiscal year, indicating order intake exceeds revenue recognition.
• Cash Flow: The company targets adjusted free cash flow conversion of 100%, a level achieved for several years.
• Pricing Power: Management reported $9 million in positive price/cost impact during the period.
• Demand Drivers: Broad-based demand is observed in life sciences and food and beverage sectors.

*Note: The evidence base for business fundamentals is anchored in 2023 transcripts and 2026 profile data. No specific 2024-2026 financial results or updated backlog figures are provided in the evidence block to confirm if the 2023 trends have persisted or accelerated through 2026.*

4. Archetype and Conviction

Archetype: Growth Leader (Layer A Classification) Fit Analysis: The company fits the Growth Leader archetype due to its high-margin service mix (60% of revenue), recurring revenue model, and exposure to high-growth end markets (life sciences, microelectronics). The "essential treatment provider" status and the complexity of water treatment requirements support a compounder narrative.

Conviction Stack Assessment:

• Thesis Strength: Low. No named secular thesis is active; the setup is tactical.
• Evidence Quality: Mixed. Strong historical fundamentals (2023 backlog, FCF conversion) are present, but the evidence is dated relative to the 2026 event date. There is no evidence of 2024-2026 performance updates.
• Setup Readiness: None. The setup is not actionable.
• Rerating Potential: Unknown. Without a confirmed breakout or a defined structural setup, the potential for a rerating cannot be quantified.

Conclusion: While the business fundamentals appear robust based on the 2023 data (strong backlog, high service mix, pricing power), the structural setup is currently non-existent. The name is a "watch list" candidate based on business quality, but it does not meet the criteria for a tradeable setup at this moment.

5. Invalidations, Strengths, and Gaps

What Would Invalidate:

• A deterioration in the book-to-bill ratio below 1.0.
• A significant drop in the service revenue mix (below 50%).

What Would Strengthen:

• A confirmed breakout above a defined resistance level with volume expansion.
• Confirmation that backlog growth has accelerated beyond the 21% YoY rate seen in 2023.
• An increase in ATR to the 4-6% range, indicating the start of a structural move.

Gaps in Evidence Base:

• Missing 2024-2026 Financials: The evidence block contains 2023 earnings transcripts and 2026 company profiles but lacks specific 2024-2026 earnings results, updated backlog figures, or margin data for the current fiscal year.
• Missing Sector Context: The sector and industry classification are not provided in the setup state.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: low Key evidence: Service revenue constitutes 60% of total revenue; backlog was up 21% YoY in Q1 2023; company targets 100% adjusted free cash flow conversion. Key risks: No active technical setup (context-only state); sub-threshold ATR (2.0%) indicates low volatility and weak structural quality; lack of 2024-2026 financial updates to confirm 2023 trends. Sizing hint: 0% position size due to lack of setup definition. Expected horizon: Indefinite until a forming or confirmed coil structure develops. Failure mode to watch: Price action remains range-bound with sub-threshold volatility, preventing any structural breakout signal.